| __timestamp | Neurocrine Biosciences, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 10811000 |
| Thursday, January 1, 2015 | 32480000 | 33001000 |
| Friday, January 1, 2016 | 68081000 | 64936000 |
| Sunday, January 1, 2017 | 169906000 | 99909000 |
| Monday, January 1, 2018 | 248932000 | 127724000 |
| Tuesday, January 1, 2019 | 354100000 | 161524000 |
| Wednesday, January 1, 2020 | 433300000 | 182933000 |
| Friday, January 1, 2021 | 583300000 | 219982000 |
| Saturday, January 1, 2022 | 752700000 | 278139000 |
| Sunday, January 1, 2023 | 887600000 | 309799000 |
| Monday, January 1, 2024 | 1007200000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Neurocrine Biosciences saw a staggering 4,800% increase in SG&A expenses, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Ultragenyx Pharmaceutical's SG&A expenses grew by approximately 2,800%, indicating a more measured approach to scaling operations.
These trends highlight the diverse strategies employed by biotech firms in managing operational costs while pursuing innovation.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Comparing SG&A Expenses: Insmed Incorporated vs Ultragenyx Pharmaceutical Inc. Trends and Insights